Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib

The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib is indicated for relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), based on its observed superior response and survival outcomes compared with salvage chemotherapy (SC). Frontline use of FLT3 tyrosine kinase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Perl, Alexander E., Hosono, Naoko, Montesinos, Pau, Podoltsev, Nikolai, Martinelli, Giovanni, Panoskaltsis, Nicki, Recher, Christian, Smith, Catherine C., Levis, Mark J., Strickland, Stephen, Röllig, Christoph, Groß-Langenhoff, Marco, Chou, Wen-Chien, Lee, Je-Hwan, Yokoyama, Hisayuki, Hasabou, Nahla, Lu, Qiaoyang, Tiu, Ramon V., Altman, Jessica K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151663/
https://www.ncbi.nlm.nih.gov/pubmed/35637252
http://dx.doi.org/10.1038/s41408-022-00677-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151663/
https://www.ncbi.nlm.nih.gov/pubmed/35637252
http://dx.doi.org/10.1038/s41408-022-00677-7

Ejemplares similares